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A B S T R A C T
Background
The loss of cholinergic, dopaminergic and noradrenergic innervations seen in Parkinson’s Disease Dementia (PDD) suggest a potential
role for cholinesterase inhibitors. Concerns have been expressed about a theoretical worsening of Parkinson’s disease related symptoms,
particularly movement symptoms.
Objectives
To assess the efficacy, safety, tolerability and health economic data relating to the use of cholinesterase inhibitors in PDD.
Search methods
The trials were identified from the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 19 April 2005
using the search term parkinson*. This register contains records from major health care databases and many ongoing trial databases
and is updated regularly.
Comprehensive searches of abstracts from major scientific meetings were performed. Pharmaceutical companies were approached for
information regarding additional and ongoing studies.
Selection criteria
Randomized, double-blind, placebo-controlled studies assessing the effectiveness of cholinesterase inhibitors in PDD. Inclusion and
exclusion criteria were stated to limit bias.
Data collection and analysis
Two reviewers (IM, CF) independently reviewed the quality of the studies utilizing criteria from the Cochrane Collaboration Hand-
book. Medications were examined separately and as a group. The outcome measures assessed were in the following domains: neu-
ropsychiatric features, cognition, global impression, daily living activities, quality of life, burden on caregiver, Parkinsonian related
symptoms, treatment acceptability as determined by withdrawal from trials, safety as determined by the frequency of adverse events,
institutionalisation, death and health economic factors.
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Main results
A detailed and systematic search of relevant databases identified one published randomized, double-blind, placebo-controlled study
(Emre 2004) involving 541 patients that compared rivastigmine with placebo. Rivastigmine produced statistically significant improve-
ments in several outcome measures. On the primary cognitive measure, the ADAS-Cog, rivastigmine was associated with a 2.80 point
ADAS-Cog improvement [WMD -2.80, 95% Cl -4.26 to -1.34, P = 0.0002] and a 2.50 point ADCS-ADL improvement [95% Cl
0.43 to 4.57, P = 0.02] relative to placebo. Clinically meaningful (moderate or marked) improvement occurred in 5.3% more patients
on rivastigmine, and meaningful worsening occurred in 10.1% more patients on placebo.
Tolerability appeared to be a significant issue. Significantly more patients on rivastigmine dropped out of the study due to adverse
events [62/362 versus 14/179, OR 2.44, 95% Cl 1.32 to 4.48, P = 0.004]. Nausea [20/179 versus 105/362, OR 3.25, 95% Cl 1.94 to
5.45, P < 0.00001], tremor [7/179 versus 37/362, OR 2.80, 95% Cl 1.22 to 6.41, P = 0.01] and in particular vomiting [3/179 versus
60/362, OR 11.66, 95% Cl 3.60 to 37.72, P < 0.0001] were significantly more common with rivastigmine. However, significantly
fewer patients died on rivastigmine than placebo [4/362 versus 7/179, OR 0.27, 95% CI 0.08 to 0.95, P = 0.04]
Authors’ conclusions
Rivastigmine appears to improve cognition and activities of daily living in patients with PDD. This results in clinically meaningful
benefit in about 15% of cases. There is a need for more studies utilising pragmatic measures such as time to residential care facility and
both patient and carer quality of life assessments. Future trials should involve other cholinesterase inhibitors, utilise tools to analyse the
data that limit any bias and measure health economic factors. It is unlikely that relying solely on the last observation carried forward
(LOCF) is sufficient. Publication of the observed case data in the largest trial would assist (Emre 2004). Adverse events were associated
with the cholinergic activity of rivastigmine, but may limit patient acceptability as evidenced by the high drop out rate in the active
arm.
P L A I N L A N G U A G E S U M M A R Y
Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD
Dementia is frequently associated with Parkinson’s Disease. While a number of neurotransmitters appear to be involved, loss of cholin-
ergic functioning is particularly associated with Parkinson’s Disease Dementia (PDD) suggesting a potential utility for cholinesterase
inhibitors. Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD.
There was a clinically meaningful benefit in 15% of patients. Efficacy in other domains requires confirmation. Tolerability in particular
nausea, vomiting and tremor appear problematic.
B A C K G R O U N D
The prevalence of dementia in Parkinson’s disease (PD) is six
times higher than in the general population (Aarsland 2001). The
prevalence of dementia in people with Parkinson’s disease varies
widely from 4% to 93%, based on study design, dementia defini-
tion and population selection, with an overall prevalence of 40%
(Cummings 1988; Emre 2003; Erkinjuntti 1997; Zhang 1993).
The condition usually develops in people over the age of 65, and
old age has been identified as a risk factor for Parkinson’s Dis-
ease Dementia (PDD) (Aarsland 2001; Aarsland 2002a; Nilsson
2004). Severe parkinsonism may be a further risk factor, but the
prospective studies are somewhat conflicting; duration of illness
does not appear to be a risk factor (Aarsland 2001; Hughes 2000).
The development of dementia associated with PD increases care-
giver distress, nursing home requirements, mortality twofold, and
reduces quality of life (Bedard 2003; Burn 2003).
Diagnostic criteria for PDD are problematic as there is inevitably
some contamination with other forms of dementia. There are con-
cerns about differentiating the condition from Alzheimer’s disease
with motor and psychotic symptoms, Dementia with Lewy bod-
ies (DLB) and subcortical vascular dementia. Additionally, cogni-
tive impairment not amounting to dementia commonly occurs in
Parkinson’s disease (Erkinjuntti 1997). The pathology and symp-
tomatology of PDDandDLB is similar, making the differential di-
2Cholinesterase inhibitors for Parkinson’s disease dementia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
agnosis particularly problematic (Aarsland 2002a; Nilsson 2004).
If the Parkinson’s disease has existed at least 12 months before the
dementia develops, PDD is considered the most appropriate diag-
nosis. If, however, dementia occurs within 12 months of the onset
of parkinsonian symptoms a diagnosis of DLB should be assigned
(McKeith 1996). The rationale for a cut off period of 12 months
is recognised to be arbitrary (McKeith 1996).
While the inter-relationships are not well established, deficits of
multiple neurotransmitter systems, and cerebral circuits result in
the cognitive symptoms of PDD (Leroi 2004). The loss of sero-
tonergic and noradrenergic innervations (nerve supplies) are im-
plicated in the cognitive deficits noted in PDD (Jellinger 1994).
Decreases in dopaminergic and especially cholinergic functioning
are central in mediating the dementia associated with PD (Burn
2003). The progressive loss of dopaminergic functioning in the
substantia nigra seen in Parkinson’s disease interferes with frontal-
subcortical dopaminergic neurons, contributing to the cognitive
impairment (Dubois 1997). The cholinergic deficit due to neu-
ronal loss in the nucleus basalis of Meynert correlates to the extent
of cognitive impairment (Nakano 1984). Cortical lesions such as
those seen in Alzheimer’s disease and DLB also occur in PDD
(Jellinger 1999). Recent studies have indicated that cholinergic
deficits as measured by choline acetyltransferase activity are more
significant in PDD compared to both Alzheimer’s disease and PD
without dementia (Tiraboschi 2000; Ziabreva 2005).
Treatment options in PDD are limited. Dopaminergic agents have
been shown to produce only limited, short-term improvements in
cognitive functioning (Kulisevsky 2000). Neuroleptic medication
could potentially aggravate anymovement disorder via antagonism
of D2 receptors (Barber 2001). This worsening of movement dis-
order in Parkinson’s disease also occurs with atypical neuroleptics
(Graham 1998). While the NMDA-receptor antagonist meman-
tinemay be a treatment option there is only very limited data (Lokk
2004). The observation that PDD is associated with decreases
in cortical cholinergic functioning implies that cholinesterase in-
hibitorsmight be beneficial (Aarsland 2002a; Perry 1985). A num-
ber open studies and small scale placebo studies have suggested
that cholinesterase inhibitors may be effective in cognitive impair-
ment associated with PD (Aarsland 2002; Aarsland 2002a; Giladi
2003; Hutchinson 1996; Leroi 2004; Reading 2001; Werber
2001). Concerns about tolerability including possible worsening
of Parkinson’s disease have been expressed. There is a need to eval-
uate the effects of this class of medication on cognition, physical
function and behavioural symptoms, as well as tolerability.
O B J E C T I V E S
To assess the efficacy, safety, and tolerability of cholinesterase in-
hibitors in PDD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized, double-blind, placebo-controlled studies assessing
the efficacy of cholinesterase inhibitors for people with PDD.
Types of participants
Patients of any age or sex diagnosed with PDD according to stan-
dardized methods such as the DSM-IV criteria (APA 1994).
Types of interventions
Any studies comparing any of the current cholinesterase in-
hibitors (donepezil, rivastigmine, galantamine and tacrine) against
placebo.
Types of outcome measures
Outcome measures that evaluated the following:
• Neuropsychiatric features, e.g., any psychiatric or
behavioural manifestations
• Cognition
• Global clinical impression
• Activities of daily living
• Quality of life
• Caregiver burden
• Parkinsonian features such as tremor and rigidity
• Acceptability of treatment, as determined by withdrawal
from trials
• Safety, as measured by the frequency and severity of adverse
events
• Institutionalization
• Health Economics
Search methods for identification of studies
The trials were identified from a last updated search of the Special-
ized Register of the Cochrane Dementia and Cognitive Improve-
ment Group on 19 April 2005 using the search term parkinson*
The Specialized Register at that time contained records from the
following databases:
• CENTRAL: January 2005 (issue 1);
• MEDLINE: 1966 to 2005/02;
• EMBASE: 1980 to 2005/01;
• PsycINFO: 1887 to 2005/01;
• CINAHL: 1982 to 2004/12;
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• SIGLE (Grey Literature in Europe): 1980 to 2004/06;
• ISTP (Index to Scientific and Technical Proceedings): to
May 2000;
• INSIDE (BL database of Conference Proceedings and
Journals): to June 2000;
• Aslib Index to Theses (UK and Ireland theses): 1970 to
March 2003;
• Dissertation Abstract (USA): 1861 to March 2003;
• ADEAR (Alzheimer’s Disease Clinical Trials Database): to
25 March 2005;
• National Research Register: issue 1/2005;
• Current Controlled trials (last searched April 2005) which
includes:
Alzheimer Society
GlaxoSmithKline
HongKong Health Services Research Fund
Medical Research Council (MRC)
NHS R&D Health Technology Assessment Programme
Schering Health Care Ltd
South Australian Network for Research on Ageing
US Dept of Veterans Affairs Cooperative Studies
National Institutes of Health (NIH)
• ClinicalTrials.gov: last searched March 2005;
• LILACS (Latin American and Caribbean Health Science
Literature): last searched April 2003
A comprehensive search of abstracts frommajor scientificmeetings
was performed.
Shire Pharmaceuticals/Janssen-Cilag, Pfizer/Eisai and Novartis (
Novartis 2005) were contacted in September 2004 for information
regarding additional and ongoing studies.
Data collection and analysis
Selection of studies:
Two reviewers (IM, CF) independently selected trials for relevance
against defined inclusion criteria from theCochraneCollaboration
Handbook (Clarke 2001). Trials that did not meet the criteria
were excluded. Reviewers’ selection of trials were compared and
the final list of studies was reached by consensus. Disagreements
were resolved by discussion and consultation with a third reviewer.
Assessment of methodological quality:
Sources of bias were considered on a study-by-study basis and
studies were excluded if two reviewers (CF, IM) agreed that bias
was significant. In these cases, exclusions were specified.
Data extraction:
Data was extracted from the published reports. The summary
statistics required for each trial and each outcome for continuous
data were the mean change from baseline, the standard error of
the mean change, and the number of patients for each treatment
group at each assessment. Where changes from baseline were not
reported, themean, standard deviation and the number of patients
for each treatment group at each time point were extracted, if
available.
For binary data the numbers in each treatment group and the
numbers experiencing the outcome of interest were sought.
The baseline assessment was defined as the latest available assess-
ment prior to randomization, but no longer than two months
prior.
For each outcome measure, data were sought on every patient ran-
domized. To allow an intention-to-treat analysis, the data were
sought irrespective of compliance, whether or not the patient was
subsequently deemed ineligible or otherwise excluded from treat-
ment or follow-up. If intention-to-treat data were not available in
the publications, “on-treatment” or the data of those who com-
plete the trial were sought and indicated as such.
In studies where a cross-over design was used, only data from the
first treatment phase after randomization were eligible for inclu-
sion.
Data from titration phases prior to the randomized phase were not
used to assess safety or efficacy because patients were usually not
randomized, nor were treatments concealed.
Rating scales: A significant number of rating scales are used to
assess outcomes within Mental Health. Scales vary in quality and
many are poorly validated.Outcomesmeasuredusingunpublished
rating scales or scales with no established reliability or validity were
excluded from the review.
Individual patient data were sought for all included studies when
the published data were inadequate.
Data analysis:
The outcomesmeasured in clinical trials of dementia and cognitive
impairment often arise fromordinal rating scales.Where the rating
scales used in the trials had a reasonably large number of ordered
categories (more than ten) the data were be treated as continuous
outcomes arising from a normal distribution.
Summary statistics (n,mean and standard deviation) were required
for each rating scale at each assessment time, for each treatment
group in each trial, for change from baseline. For crossover trials
only the data from the first treatment period were used.
When change from baseline results was not reported, the required
summary statistics were calculated from the baseline and assess-
ment time treatment group means and standard deviations. In
this case a zero correlation between the measurements at baseline
and assessment time were assumed. This method overestimates the
standard deviation of the change from baseline, but this conserva-
tive approach is considered to be preferable in a meta-analysis.
Themeta-analysis required the combination of data from the trials
that may not have used the same rating scale to assess an outcome.
The measure of the treatment difference for any outcome was the
weighted mean difference when the pooled trials used the same
rating scale or test, and the standardised mean difference, which
is the absolute mean difference divided by the standard deviation
when different rating scales or tests were used.
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The duration of the trials may vary considerably. If the range was
considered too great to combine all trials into one meta-analysis, it
was divided into smaller time periods and a separate meta-analysis
conducted for each period. Some trials contributed data to more
than one time period if multiple assessments were done.
For binary outcomes, such as clinical improvement or no clinical
improvement, the odds ratio was used tomeasure treatment effect.
A weighted estimate of the typical treatment effect across trials was
calculated.
Overall estimates of the treatment difference were presented. In all
cases the overall estimate from a fixed effects model was presented
and a test for heterogeneity using a standard chi-square statistic
or the I2 statistic were performed. If, however, there was evidence
of heterogeneity of the treatment effect between trials then either
only homogeneous results were pooled, or a random-effects model
was used (in which case the confidence intervals were broader than
those of a fixed-effects model).
Subgroup analysis:
Where relevant, and data were available, subgroup analysis in-
cluded age, sex, type and severity of impairment, duration of treat-
ment and details of individual cholinesterase inhibitors.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
One 24-week study comparing rivastigmine with placebo met the
inclusion criteria (Emre 2004). Five hundred and forty-one pa-
tients were randomized in a ratio of 2 to 1 to receive rivastigmine
or placebo. Rivastigmine was started at a dose of 1.5 mg twice
daily and increased to a maximum of 6 mg twice daily over 16
weeks. Baseline characteristics were similar in both groups. The
mean age and percentage female was 72.8 years and 35.4% with
rivastigmine, and 72.4 years and 34.6% with placebo. No patients
with a black or oriental race or ethnic group were included in the
study population. Patients had a diagnosis of mild to moderately
severe dementia, which had developed at least 2 years after PD was
diagnosed. The mean MMSE was 19.4 (rivastigmine) and 19.2
(placebo). Most patients (91.1%) had one or more co-existing
medical condition most commonly a psychiatric disorder (40.3%)
and a vascular disorder (35.5%). The most common CNS med-
ications were levodopa (95.6% in rivastigmine group, 94.4% in
placebo group) and dopamine agonists (45.6% with rivastigmine
and 46.4% with placebo). Details of non-CNS medications were
not given. For full details of the study, see table of included studies.
Scales:
The primary outcome measures were:
1. The Alzheimer’s Disease Assessment Scale - Cognitive sub-scale
(ADAS-Cog) (Rosen 1984). The ADAS-Cog contains 11 different
tests, spoken language ability (0 to 5), comprehension of spoken
language (0 to 5), recall of test instructions (0 to 5), word finding
difficulty (0 to 5), following commands (0 to 5), naming objects
(0 to 5), construction drawing (0 to 5), ideational praxis (0 to 5),
orientation (0 to 8), word recall (0 to 10) and word recognition
(0 to 12). The total score ranges from 0 to 70 with higher scores
indicating greater impairment.
2. The Alzheimer’s Disease Cooperative Study - Clinician’s Global
Impression of Change (ADCS-CGIC) (Schneider 1997) evaluates
the global change in functioning from baseline. A score of 1 indi-
cates marked improvement, 2 indicates moderate improvement,
3 indicates minimal improvement, 4 indicates no change, 5 indi-
cates minimal worsening, 6 indicates moderate worsening and 7
indicates marked worsening.
The secondary outcome measures were :
1. The Mini Mental State Examination (MMSE) (Folstein 1975)
evaluates cognition in five domains; orientation, immediate recall,
attention and calculation, delayed recall and language. The test
takes 15 minutes to administer with scores ranging from 0 (severe
impairment) to 30 (normal).
2. The Alzheimer’s Disease Cooperative Study - Activities of Daily
Living (ADCS-ADL) (Galasko 1997) evaluates activities of daily
living. Scores range from 0 to 78 with higher scores indicating
better functioning.
3. The 10-item Neuropsychiatric Inventory (NPI) (Cummings
1994). The NPI is a relatively brief interview that assesses 10 types
of behavourial disturbance; delusions, hallucinations, dysphoria,
anxiety, agitation/aggression, euphoria, disinhibition, irritability/
lability, apathy and aberrant motor behaviour. Scores range from
0 (normal) to 120 (severely disturbed).
4. The Cognitive Drug Research (CDR) Computerized Assess-
ment System (Simpson 1991) power of attention tests evaluate
simple and complex reaction times and digit vigilance. Scores are
measured in milliseconds with higher scores indicating a worse
performance.
5. TheDelis-Kaplan Executive Function System (D-KEFS) Verbal
Fluency test (Delis 2001) requires patients to produce as many
words as they can in one minute starting with a particular letter.
Higher scores indicate better performance.
6. The Ten Point Clock-Drawing test (Manos 1994). Scores range
from 0 to 10 with higher results indicating better performance.
7. The Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn
1987) motor subsection was utilised to assess changes in motor
function and parkinsonian symptoms. Scores range from 0 to 108
with higher scores indicating more severe motor symptoms.
Risk of bias in included studies
The included study (Emre 2004) randomly assigned patients to ri-
vastigmine or placebo in a ratio of 2 to 1. At each treatment centre
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patients were allocated the lowest available identification number.
Automated random treatment allocation was conducted with a
validated systemmanaged byNovartis Drug SupplyManagement.
Blocking was carried out according to study centre. Personnel di-
rectly involved in the study and patients were blind to allocation.
There was a 24.2% drop-out rate, the main reason being adverse
events. The last observation carried forward (LOCF) was utilised
if follow-up data were lacking. Observed case results were reported
as being ’consistent with results in the primary population’ (Emre
2004).
Effects of interventions
One study comparing rivastigmine with placebo in 541 patient
met the inclusion criteria (Emre 2004).
• Alzheimer’s Disease Assessment Scale - Cognitive sub-scale
(ADAS-Cog)
The ADAS-Cog found that using the LOCF the change score from
baseline to week 24 significantly favoured rivastigmine [WMD -
2.80, 95% Cl -4.26 to -1.34, P = 0.0002].
• Alzheimer’s Disease Cooperative Study - Clinician’s Global
Impression of Change (ADCS-CGIC)
The ADCS-CGIC found that using the LOCF the change score
from baseline to week 24 significantly favoured rivastigmine
[WMD -0.50, 95% Cl -0.77 to -0.23, P = 0.0004]. Clinically
meaningful (moderate or marked) improvement was observed in
19.8% of patients in the rivastigmine group and 14.5% of those
in the placebo group. Clinically meaningful (moderate or marked)
worsening was observed in 13.0% patients in the rivastigmine
group and 23.1% of those in the placebo group.
• The Mini Mental State Examination (MMSE)
The MMSE found that using the LOCF the change score from
baseline to week 24 significantly favoured rivastigmine [WMD
1.00, 95% Cl 0.33 to 1.67, P = 0.003].
• Alzheimer’s Disease Cooperative Study - Activities of Daily
Living (ADCS-ADL)
The ADCS-ADL found that using the LOCF the change score
from baseline to week 24 significantly favoured rivastigmine
[WMD 2.50, 95% Cl 0.43 to 4.57, P = 0.02].
• The 10-item Neuropsychiatric Inventory (NPI)
The 10-item test found that using the LOCF the change score from
baseline to week 24 significantly favoured rivastigmine [WMD -
2.00, 95% Cl -3.91 to -0.09, P = 0.04].
• Cognitive Drug Research (CDR) Computerized
Assessment System - Power of Attention battery (POA)
The CDR POA battery found that using the LOCF there was
no statistically significant group difference in the change score
from baseline to week 24 [WMD -173.70, 95% Cl -471.23 to
123.83, P = 0.25]. The improvement on CDR power of attention
tests is presented as statistically significant in Emre et al, where
it was modeled, but was not statistically significant when the raw
difference was entered into RevMan.
• Delis-Kaplan Executive Function System (D-KEFS) Verbal
Fluency test
The D-KEFS found that using the LOCF the change score from
baseline to week 24 significantly favoured rivastigmine [WMD
2.80, 95% CL 1.47 to 4.13, P < 0.0001]. This test was not per-
formed at all centres.
• Unified Parkinson’s Disease Rating Scale (UPDRS)
Full UPDRS results were not reported, but there was no signifi-
cant group difference in UPDRS motor scores (P=0.83) including
tremor type events (P=0.84).
Adverse events:
Significantly fewer patients on placebo suffered one or more ad-
verse event than on rivastigmine [127/179 versus 303/362, OR
2.10, 95%Cl 1.37 to 3.22, P = 0.0006]. Compared to rivastigmine
significantly fewer patients on placebo experienced nausea [20/
179 versus 105/362,OR3.25, 95%Cl 1.94 to 5.45, P < 0.00001],
vomiting [3/179 versus 60/362, OR11.66, 95%Cl 3.60 to 37.72,
P < 0.0001], tremor [7/179 versus 37/362, OR 2.80, 95% Cl
1.22 to 6.41, P = 0.01] or dizziness [2/179 versus 21/362, OR
5.45, 95% Cl 1.26 to 23.51, P = 0.02]. This increased incidence
of tremor appears to contradict the UPDRS results. One possible
explanation is that the UPDRS motor subscale lacks sensitivity to
detect an increase in tremor in patients suffering from dementia.
Significantly more patients on placebo than on rivastigmine expe-
rienced orthostatic hypotension [9/179 versus 6/362, OR 0.32,
95%Cl 0.11 to 0.91, P = 0.03] and hallucinations [17/179 versus
17/362, OR 0.47, 95% Cl 0.23 to 0.94, P = 0.03].
Although the confidence intervals are wide, patients taking ri-
vastigmine were significantly less likely to die within the 24 weeks
of the study than those taking placebo [4/362 versus 7/179, OR
0.27, 95% CI 0.08 to 0.95, P = 0.04].
There were no significant group differences in terms of the in-
cidence of diarrhoea, anorexia, falls, hypotension, constipation,
confusion and serious adverse events.
At 24 weeks the death rate was significantly higher with placebo
[7/179 versus 4/362, OR 0.27, 95% Cl 0.08 to 0.95, P = 0.04].
Drop out rates:
Significantly more patients on rivastigmine dropped out before
the end of treatment at 24 weeks due to any reason [99/362 versus
32/179, OR 1.73, 95% Cl 1.11 to 2.70, P = 0.02] or due to an
adverse event [62/362 versus 14/179, OR 2.44, 95% Cl 1.32 to
4.48, P = 0.004]
D I S C U S S I O N
When evaluating the evidence base for any treatment three key
issues should be considered: the treatment, the study population
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and the outcome. Currently there is only one RCT reported inves-
tigating the efficacy of rivastigmine that met our inclusion criteria
(Emre 2004). We are, therefore, unable to comment on the use
of other cholinesterase inhibitors. The population in the single
included study was limited to patients with mild to moderately
severe dementia and excluded black or oriental racial groups.
The primary outcome measures and all but one of the secondary
measures indicated a statistically significant effect. The 2.80 point
improvement on the ADAS-Cog at 24 weeks is comparable to
that noted with cholinesterase inhibitors in Alzheimer’s disease
and is equivalent to a delay of 6 months in the disease pathology.
Furthermore, the functional and global measures indicated sta-
tistical significance. The results must be treated with caution for
three reasons. First, in a degenerative disorder the use of LOCF
may enhance the final outcome. This effect may be significant if
there is a high drop out rate and when there is differential drop
out rate between study arms. Thus the use of LOCF may have
biased the results in favour of active therapy. Second, tolerability
issues may negatively influence patient acceptability as evidenced
by the higher drop out rate in the active arm. Third, statistical
significance does not always equate with clinical significance. For
example, a 2-point difference on the 10-item NPI (range of scores
0 to 120) is unlikely to be clinically significant (Fox 2003; Sink
2005). On the other hand, there was a 5.3% difference in the rate
of detectable changes that had a positive effect on clinical status,
and a 10.1% difference in changes that had a detectable negative
effect on clinical status. These differences both favoured rivastig-
mine over placebo.
Unfortunately, the study did not report the effect of rivastigmine
in PDD on institutionalization rates, quality of life measures for
both patients and carers and health economic factors.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is clear evidence from one RCT that rivastigmine had a
moderate effect on cognition and to a lesser extent ADL in patients
with PDD. Rivastigmine has a clinically meaningful, beneficial
effect in 15% of cases of PDD. The importance of this clinical
effect will depend on the individual patient’s context. No infor-
mation is available on cost-effectiveness. Tolerability issues appear
significant and will require careful management.
Implications for research
Studies are required to confirmclear clinically significant efficacy as
well as statistically significant efficacy in illness domains in addition
to cognition. Studies should utilise other methods in addition
to the last observation carried forward to analyse the data and
assess health economic factors. Long term trials with clinically in
addition to statistically significant outcome measures should be
linked to economic analysis of cost-effectiveness. Data is required
for other cholinesterase inhibitors and cognitive enhancers and in
patients from black and oriental ethnic groupings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Emre 2004
Methods Randomised,
multicentre,
double-blind,
placebo-controlled.
Duration: 24 weeks
Participants Countries: Austria, Belgium, Canada, France, Germany, Italy, Holland, Norway, Portugal, Spain, Turkey,
UK.
No. of centres: not stated.
Diagnosis: PD by UK Parkinson’s Disease Society Brain Bank criteria; Dementia by DSM-IV (dementia
due to Parkinson’s disease code 294.1)
Inclusions: MMSE 10 to 24; onset of symptoms of dementia more than 2 years after diagnosis of PD;
regular caregiver.
Exclusions: primary neurodegenerative disease other than PD or dementia; history major depression; pres-
ence of active uncontrolled seizure disorder; disability or unstable disease unrelated to PD; hypersensitivity
rivastigmine or similar drugs; use cholinesterase inhibitor or anticholinergic drug.
Number of patients: 541.
Interventions Route: oral
Treatment: rivastigmine commenced at 1.5mg twice daily and increased according to tolerability by 3mg
daily at intervals of at least 4 weeks over a 16 week period
Outcomes Primary outcome measures: Alzheimer’s Disease Assessment Scale - Cognitive sub-scale (ADAS-Cog);
Alzheimer’s Disease Cooperative Study - Clinician’s Global Impression of Change (ADCS-CGIC)
Secondary measures: Mini Mental State Examination (MMSE); Alzheimer’s Disease Cooperative Study
- Activities of Daily Living (ADCS-ADL); Neuropsychiatric Inventory (NPI); Cognitive Drug Research
(CDR) Computerized Assessment System power of attention tests; Delis-Kaplan Executive Function
System (D-KEFS) Verbal Fluency test; Ten Point Clock-Drawing test; Unified Parkinson’s Disease Rating
Scale (UPDRS)
Notes - data was analysed with the LOCF
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aarsland 2002 Open label study
Aarsland 2002a Diagnostic criteria outside specification
(Diagnostic criteria for PDD - DSM-IV PDD or probable PDD)
(Diagnostic criteria for PD - not stated)
Bergman 2002 Open label study
Bergman 2003 Open label study; trial of people with Alzheimer’s disease, not Parkinson’s
Fabbrini 2002 Open label study
Fogelson 2003 Open label study; non standard outcome measures
Foy 2000 Diagnostic criteria outside specification
Giladi 2003 Open label study
Hutchinson 1996 Open label study
Korczyn 2001 Open label study
Leroi 2004 Diagnostic criteria outside specification
(Diagnostic criteria for PDD - DSM-IV PDD or cognitive impairment secondary to PD)
McKeith 2000a Open label exploratory trial; 20 weeks acitve treatment then 6 weeks of withdrawal
Reading 2001 Open label study
Van Laar 2001 Open label study
Werber 2001 Open label study
Characteristics of ongoing studies [ordered by study ID]
Anon 2004a
Trial name or title Donepezil for dementia in Parkinson’s disease: A randomized double blinded placebo controlled crossover
trial
Methods
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Anon 2004a (Continued)
Participants N = 28
Country = USA
Duration = 26 weeks
Interventions Donepezil +// Placebos//
Outcomes -ADAS/cog
-cognitive function /
-activities of daily living
-mood
-quality of life
-side effects
-motor performance
Starting date February 2002
Contact information Study ID numbers 020115; 02-N-0115//NLM identifier NCT00030979
Notes This study does definitely not belong to Leroy 2004
Marion 2003
Trial name or title An open 24 week prospective, randomised, double-blind placebo controlled prallel group study of efficacy,
tolerability and safety of 3-12mg/day of exelon and exelon (rivastigmine) capsules in patients with Parkinson’s
disease dementia
Methods
Participants N = 10
Country = UK
Duration = 24 weeks
Interventions Rivastigmine +// Dosage of Drug +//Placebos
Outcomes unclear
Starting date due to end 31/12/05
Contact information Marie-Helene.Marion@stgeorges.nhs.uk
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Rivastigmine (3-12mg/day) vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ADAS-Cog (change from
baseline at 24 weeks) LOCF
1 490 Mean Difference (IV, Fixed, 95% CI) -2.8 [-4.26, -1.34]
2 ADCS-CGIC (change from
baseline at 24 weeks) LOCF
1 494 Mean Difference (IV, Fixed, 95% CI) -0.5 [-0.77, -0.23]
3 ADCS-ADL (change from
baseline at 24 weeks) LOCF
1 498 Mean Difference (IV, Fixed, 95% CI) 2.5 [0.43, 4.57]
4 NPI-10 (change from baseline at
24 weeks) LOCF
1 500 Mean Difference (IV, Fixed, 95% CI) -2.0 [-3.91, -0.09]
5 MMSE (change from baseline at
24 weeks) LOCF
1 501 Mean Difference (IV, Fixed, 95% CI) 1.0 [0.33, 1.67]
6 CDR (change from baseline at
24 weeks) LOCF
1 486 Mean Difference (IV, Fixed, 95% CI) -173.7 [-471.23,
123.83]
7 D-KEFS (change from baseline
at 24 weeks) LOCF
1 402 Mean Difference (IV, Fixed, 95% CI) 2.8 [1.47, 4.13]
8 Withdrawals before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 1.73 [1.11, 2.70]
9 Withdrawals due to adverse
event before end of treatment
at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 2.44 [1.32, 4.48]
10 Number of deaths before end
of treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.08, 0.95]
11 At least one adverse event
before end of treatment at 24
weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 2.10 [1.37, 3.22]
12 At least one adverse event of
nausea before end of treatment
at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 3.25 [1.94, 5.45]
13 At least one adverse event
of vomiting before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 11.66 [3.60, 37.72]
14 At least one adverse event of
tremor before end of treatment
at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 2.80 [1.22, 6.41]
15 At least one adverse event
of diarrhoea before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 1.65 [0.73, 3.73]
16 At least one adverse event
of anorexia before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 2.25 [0.84, 6.05]
17 At least one adverse event of a
fall before end of treatment at
24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.44, 2.00]
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18 At least one adverse event
of dizziness before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 5.45 [1.26, 23.51]
19 At least one adverse event of
hypotension before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.33]
20 At least one adverse event of
constipation before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.32, 1.47]
21 At least one adverse event of
hallucinations before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.23, 0.94]
22 At least one adverse event
of confusion before end of
treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.27, 1.46]
23 At least one adverse event of
orthostatic hypotension before
end of treatment at 24 weeks
1 541 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.11, 0.91]
Analysis 1.1. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 1 ADAS-Cog (change from
baseline at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 1 ADAS-Cog (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 329 -2.1 (8.2) 161 0.7 (7.5) 100.0 % -2.80 [ -4.26, -1.34 ]
Total (95% CI) 329 161 100.0 % -2.80 [ -4.26, -1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours rivastigmine Favours placebo
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Analysis 1.2. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 2 ADCS-CGIC (change from
baseline at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 2 ADCS-CGIC (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 329 3.8 (1.4) 165 4.3 (1.5) 100.0 % -0.50 [ -0.77, -0.23 ]
Total (95% CI) 329 165 100.0 % -0.50 [ -0.77, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours rivastigmine Favours placebo
Analysis 1.3. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 3 ADCS-ADL (change from
baseline at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 3 ADCS-ADL (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 333 -1.1 (12.6) 165 -3.6 (10.3) 100.0 % 2.50 [ 0.43, 4.57 ]
Total (95% CI) 333 165 100.0 % 2.50 [ 0.43, 4.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours rivastigmine
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Analysis 1.4. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 4 NPI-10 (change from
baseline at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 4 NPI-10 (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 334 -2 (10) 166 0 (10.4) 100.0 % -2.00 [ -3.91, -0.09 ]
Total (95% CI) 334 166 100.0 % -2.00 [ -3.91, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours rivastigmine Favours placebo
Analysis 1.5. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 5 MMSE (change from baseline
at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 5 MMSE (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 335 0.8 (3.8) 166 -0.2 (3.5) 100.0 % 1.00 [ 0.33, 1.67 ]
Total (95% CI) 335 166 100.0 % 1.00 [ 0.33, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0034)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours placebo Favours rivastigmine
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Analysis 1.6. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 6 CDR (change from baseline
at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 6 CDR (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 328 -31 (989.8) 158 142.7 (1780.2) 100.0 % -173.70 [ -471.23, 123.83 ]
Total (95% CI) 328 158 100.0 % -173.70 [ -471.23, 123.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours rivastigmine Favours placebo
Analysis 1.7. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 7 D-KEFS (change from
baseline at 24 weeks) LOCF.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 7 D-KEFS (change from baseline at 24 weeks) LOCF
Study or subgroup Rivastigmine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emre 2004 258 1.7 (6.8) 144 -1.1 (6.4) 100.0 % 2.80 [ 1.47, 4.13 ]
Total (95% CI) 258 144 100.0 % 2.80 [ 1.47, 4.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours rivastigmine
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Analysis 1.8. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 8 Withdrawals before end of
treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 8 Withdrawals before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 99/362 32/179 100.0 % 1.73 [ 1.11, 2.70 ]
Total (95% CI) 362 179 100.0 % 1.73 [ 1.11, 2.70 ]
Total events: 99 (Rivastigmine), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.9. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 9 Withdrawals due to adverse
event before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 9 Withdrawals due to adverse event before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 62/362 14/179 100.0 % 2.44 [ 1.32, 4.48 ]
Total (95% CI) 362 179 100.0 % 2.44 [ 1.32, 4.48 ]
Total events: 62 (Rivastigmine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.10. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 10 Number of deaths before
end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 10 Number of deaths before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 4/362 7/179 100.0 % 0.27 [ 0.08, 0.95 ]
Total (95% CI) 362 179 100.0 % 0.27 [ 0.08, 0.95 ]
Total events: 4 (Rivastigmine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.11. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 11 At least one adverse event
before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 11 At least one adverse event before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 303/362 127/179 100.0 % 2.10 [ 1.37, 3.22 ]
Total (95% CI) 362 179 100.0 % 2.10 [ 1.37, 3.22 ]
Total events: 303 (Rivastigmine), 127 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.42 (P = 0.00064)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Analysis 1.12. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 12 At least one adverse event
of nausea before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 12 At least one adverse event of nausea before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 105/362 20/179 100.0 % 3.25 [ 1.94, 5.45 ]
Total (95% CI) 362 179 100.0 % 3.25 [ 1.94, 5.45 ]
Total events: 105 (Rivastigmine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.46 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
Analysis 1.13. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 13 At least one adverse event
of vomiting before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 13 At least one adverse event of vomiting before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 60/362 3/179 100.0 % 11.66 [ 3.60, 37.72 ]
Total (95% CI) 362 179 100.0 % 11.66 [ 3.60, 37.72 ]
Total events: 60 (Rivastigmine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.10 (P = 0.000042)
0.01 0.1 1 10 100
Favours rivastigmine Favours placebo
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Analysis 1.14. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 14 At least one adverse event
of tremor before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 14 At least one adverse event of tremor before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 37/362 7/179 100.0 % 2.80 [ 1.22, 6.41 ]
Total (95% CI) 362 179 100.0 % 2.80 [ 1.22, 6.41 ]
Total events: 37 (Rivastigmine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
Analysis 1.15. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 15 At least one adverse event
of diarrhoea before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 15 At least one adverse event of diarrhoea before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 26/362 8/179 100.0 % 1.65 [ 0.73, 3.73 ]
Total (95% CI) 362 179 100.0 % 1.65 [ 0.73, 3.73 ]
Total events: 26 (Rivastigmine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Analysis 1.16. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 16 At least one adverse event
of anorexia before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 16 At least one adverse event of anorexia before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 22/362 5/179 100.0 % 2.25 [ 0.84, 6.05 ]
Total (95% CI) 362 179 100.0 % 2.25 [ 0.84, 6.05 ]
Total events: 22 (Rivastigmine), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
Analysis 1.17. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 17 At least one adverse event
of a fall before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 17 At least one adverse event of a fall before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 21/362 11/179 100.0 % 0.94 [ 0.44, 2.00 ]
Total (95% CI) 362 179 100.0 % 0.94 [ 0.44, 2.00 ]
Total events: 21 (Rivastigmine), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Analysis 1.18. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 18 At least one adverse event
of dizziness before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 18 At least one adverse event of dizziness before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 21/362 2/179 100.0 % 5.45 [ 1.26, 23.51 ]
Total (95% CI) 362 179 100.0 % 5.45 [ 1.26, 23.51 ]
Total events: 21 (Rivastigmine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
0.01 0.1 1 10 100
Favours rivastigmine Favours placebo
Analysis 1.19. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 19 At least one adverse event
of hypotension before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 19 At least one adverse event of hypotension before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 19/362 14/179 100.0 % 0.65 [ 0.32, 1.33 ]
Total (95% CI) 362 179 100.0 % 0.65 [ 0.32, 1.33 ]
Total events: 19 (Rivastigmine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Analysis 1.20. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 20 At least one adverse event
of constipation before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 20 At least one adverse event of constipation before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 17/362 12/179 100.0 % 0.69 [ 0.32, 1.47 ]
Total (95% CI) 362 179 100.0 % 0.69 [ 0.32, 1.47 ]
Total events: 17 (Rivastigmine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
Analysis 1.21. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 21 At least one adverse event
of hallucinations before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 21 At least one adverse event of hallucinations before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 17/362 17/179 100.0 % 0.47 [ 0.23, 0.94 ]
Total (95% CI) 362 179 100.0 % 0.47 [ 0.23, 0.94 ]
Total events: 17 (Rivastigmine), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Analysis 1.22. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 22 At least one adverse event
of confusion before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 22 At least one adverse event of confusion before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 13/362 10/179 100.0 % 0.63 [ 0.27, 1.46 ]
Total (95% CI) 362 179 100.0 % 0.63 [ 0.27, 1.46 ]
Total events: 13 (Rivastigmine), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
Analysis 1.23. Comparison 1 Rivastigmine (3-12mg/day) vs placebo, Outcome 23 At least one adverse event
of orthostatic hypotension before end of treatment at 24 weeks.
Review: Cholinesterase inhibitors for Parkinson’s disease dementia
Comparison: 1 Rivastigmine (3-12mg/day) vs placebo
Outcome: 23 At least one adverse event of orthostatic hypotension before end of treatment at 24 weeks
Study or subgroup Rivastigmine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emre 2004 6/362 9/179 100.0 % 0.32 [ 0.11, 0.91 ]
Total (95% CI) 362 179 100.0 % 0.32 [ 0.11, 0.91 ]
Total events: 6 (Rivastigmine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
0.1 0.2 0.5 1 2 5 10
Favours rivastigmine Favours placebo
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Date Event Description
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